17.76
price up icon3.98%   0.68
pre-market  プレマーケット:  17.97   0.21   +1.18%
loading
前日終値:
$17.08
開ける:
$17.15
24時間の取引高:
7.45M
Relative Volume:
1.50
時価総額:
$1.91B
収益:
$45.97M
当期純損益:
$-508.80M
株価収益率:
-3.2409
EPS:
-5.48
ネットキャッシュフロー:
$-382.65M
1週間 パフォーマンス:
+43.11%
1か月 パフォーマンス:
+68.82%
6か月 パフォーマンス:
+90.76%
1年 パフォーマンス:
-17.28%
1日の値動き範囲:
Value
$17.11
$18.57
1週間の範囲:
Value
$13.00
$18.57
52週間の値動き範囲:
Value
$5.90
$21.87

Intellia Therapeutics Inc Stock (NTLA) Company Profile

Name
名前
Intellia Therapeutics Inc
Name
セクター
Healthcare (1150)
Name
電話
857-285-6200
Name
住所
40 ERIE STREET, CAMBRIDGE, MA
Name
職員
598
Name
Twitter
@intelliatweets
Name
次回の収益日
2024-11-07
Name
最新のSEC提出書
Name
NTLA's Discussions on Twitter

NTLA を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
NTLA
Intellia Therapeutics Inc
17.76 1.83B 45.97M -508.80M -382.65M -5.48
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
376.62 97.36B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
576.98 60.19B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
458.37 59.56B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
729.76 44.94B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
329.84 36.14B 3.81B -644.79M -669.77M -6.24

Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-04-21 アップグレード Wolfe Research Peer Perform → Outperform
2025-03-05 開始されました H.C. Wainwright Buy
2025-02-28 ダウングレード Goldman Neutral → Sell
2025-02-28 ダウングレード JP Morgan Overweight → Neutral
2025-01-27 ダウングレード Morgan Stanley Overweight → Equal-Weight
2024-02-23 ダウングレード Goldman Buy → Neutral
2024-02-15 開始されました Wolfe Research Peer Perform
2023-04-13 開始されました Canaccord Genuity Buy
2023-03-21 開始されました Bernstein Outperform
2023-03-14 アップグレード BMO Capital Markets Market Perform → Outperform
2023-02-01 開始されました Cantor Fitzgerald Overweight
2023-01-24 アップグレード Citigroup Sell → Neutral
2023-01-19 ダウングレード JMP Securities Mkt Outperform → Mkt Perform
2022-10-11 開始されました Morgan Stanley Overweight
2022-09-21 開始されました JP Morgan Overweight
2022-09-01 開始されました Citigroup Sell
2022-06-17 開始されました BMO Capital Markets Market Perform
2022-06-16 開始されました BofA Securities Buy
2022-04-28 開始されました Credit Suisse Outperform
2022-02-18 開始されました William Blair Outperform
2022-02-07 アップグレード Oppenheimer Perform → Outperform
2022-01-31 開始されました Cowen Outperform
2022-01-07 開始されました Piper Sandler Overweight
2021-10-05 開始されました Guggenheim Buy
2021-09-24 開始されました Stifel Buy
2021-06-28 繰り返されました H.C. Wainwright Buy
2021-06-11 開始されました H.C. Wainwright Buy
2021-05-07 アップグレード ROTH Capital Neutral → Buy
2021-05-04 開始されました RBC Capital Mkts Outperform
2021-03-04 開始されました JMP Securities Mkt Outperform
2020-12-22 ダウングレード Robert W. Baird Outperform → Neutral
2020-10-27 開始されました Truist Buy
2020-10-14 開始されました Wells Fargo Overweight
2020-09-18 開始されました Goldman Buy
2020-02-28 アップグレード Oppenheimer Perform → Outperform
2020-02-14 ダウングレード Wedbush Outperform → Neutral
2019-11-01 アップグレード Raymond James Mkt Perform → Outperform
2019-07-09 開始されました Robert W. Baird Outperform
2019-06-10 開始されました ROTH Capital Neutral
2019-05-03 アップグレード Wedbush Neutral → Outperform
2019-04-12 開始されました Evercore ISI Outperform
2018-11-02 ダウングレード Wedbush Outperform → Neutral
2018-10-29 開始されました Credit Suisse Neutral
2018-09-21 開始されました Raymond James Mkt Perform
2018-05-15 アップグレード Chardan Capital Markets Neutral → Buy
2018-03-08 開始されました JMP Securities Mkt Outperform
2017-11-01 繰り返されました Jefferies Buy
2017-06-22 再開されました Jefferies Buy
2017-03-28 開始されました Chardan Capital Markets Buy
2016-08-05 アップグレード Jefferies Hold → Buy
すべてを表示

Intellia Therapeutics Inc (NTLA) 最新ニュース

pulisher
Sep 24, 2025

Cardiac Amyloidosis Pipeline 2025: Pioneering Clinical Developments by 20+ Global Leaders – DelveInsight | Featuring Eidos Therapeutics, Intellia Therapeutics, Novo Nordisk, Alnylam Pharmaceuticals - Barchart.com

Sep 24, 2025
pulisher
Sep 24, 2025

Intellia Therapeutics (NASDAQ:NTLA) Shares Up 8%What's Next? - MarketBeat

Sep 24, 2025
pulisher
Sep 24, 2025

Intellia Therapeutics (NASDAQ:NTLA) Earns "Market Perform" Rating from JMP Securities - MarketBeat

Sep 24, 2025
pulisher
Sep 24, 2025

Intellia Therapeutics (NASDAQ:NTLA) Price Target Raised to $30.00 at HC Wainwright - MarketBeat

Sep 24, 2025
pulisher
Sep 23, 2025

Intellia to present data on CRISPR therapy for ATTR amyloidosis By Investing.com - Investing.com Nigeria

Sep 23, 2025
pulisher
Sep 23, 2025

Voya Investment Management LLC Purchases 179,180 Shares of Intellia Therapeutics, Inc. $NTLA - MarketBeat

Sep 23, 2025
pulisher
Sep 23, 2025

Intellia Therapeutics (NASDAQ:NTLA) Sees Unusually-High Trading VolumeStill a Buy? - MarketBeat

Sep 23, 2025
pulisher
Sep 23, 2025

Traders Purchase High Volume of Intellia Therapeutics Call Options (NASDAQ:NTLA) - MarketBeat

Sep 23, 2025
pulisher
Sep 22, 2025

Intellia rises after completion of enrollment in angioedema study - MSN

Sep 22, 2025
pulisher
Sep 22, 2025

Intellia to present data on CRISPR therapy for ATTR amyloidosis - Investing.com India

Sep 22, 2025
pulisher
Sep 22, 2025

Global clinical trial of HAE gene-editing therapy now fully enrolled - Angioedema News

Sep 22, 2025
pulisher
Sep 22, 2025

Cathie Wood's ARK Innovation ETF Expands Holdings in Intellia Th - GuruFocus

Sep 22, 2025
pulisher
Sep 22, 2025

Intellia Therapeutics to Present Long-Term Data on Investigational Nex-z for ATTR Amyloidosis at International Conference in Italy - Quiver Quantitative

Sep 22, 2025
pulisher
Sep 22, 2025

Intellia Therapeutics to Present Longer-Term Data from the Ongoing Phase 1 Clinical Trial of Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy - The Manila Times

Sep 22, 2025
pulisher
Sep 22, 2025

Intellia Therapeutics to Present Longer-Term Data from the - GlobeNewswire

Sep 22, 2025
pulisher
Sep 22, 2025

3 Years of Data: Intellia's Groundbreaking CRISPR Gene Therapy for Rare ATTR Disease Shows Long-term Results - Stock Titan

Sep 22, 2025
pulisher
Sep 21, 2025

Energy Moves: Can Intellia Therapeutics Inc navigate macro headwinds2025 Trade Ideas & Reliable Momentum Entry Alerts - خودرو بانک

Sep 21, 2025
pulisher
Sep 21, 2025

Intellia Therapeutics (NASDAQ:NTLA) Shares Gap UpWhat's Next? - MarketBeat

Sep 21, 2025
pulisher
Sep 20, 2025

Profit Review: Will Intellia Therapeutics Inc face regulatory challenges2025 Market WrapUp & Low Drawdown Momentum Ideas - خودرو بانک

Sep 20, 2025
pulisher
Sep 20, 2025

Guidance Update: Will Intellia Therapeutics Inc. outperform tech stocksEarnings Performance Report & Long-Term Capital Growth Strategies - khodrobank.com

Sep 20, 2025
pulisher
Sep 20, 2025

Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA) and Zymeworks (ZYME) - The Globe and Mail

Sep 20, 2025
pulisher
Sep 20, 2025

Intellia Therapeutics (NASDAQ:NTLA) Shares Up 6.3%Time to Buy? - MarketBeat

Sep 20, 2025
pulisher
Sep 19, 2025

Market Wrap: Can Intellia Therapeutics Inc stock double in the next yearSell Signal & Technical Confirmation Alerts - khodrobank.com

Sep 19, 2025
pulisher
Sep 19, 2025

Is Intellia Therapeutics Inc in a consolidation phaseJuly 2025 Trends & Free High Return Stock Watch Alerts - خودرو بانک

Sep 19, 2025
pulisher
Sep 19, 2025

Why Intellia ($NTLA) Just Had A Major Breakout - MSN

Sep 19, 2025
pulisher
Sep 19, 2025

Intellia Therapeutics: Full Trial Enrollment Wows MarketUnderlines Buy Thesis (NTLA) - Seeking Alpha

Sep 19, 2025
pulisher
Sep 19, 2025

NTLA Completes Enrollment in Pivotal Study on HAE Candidate, Stock Up - sharewise.com

Sep 19, 2025
pulisher
Sep 19, 2025

Intellia Therapeutics stock price target raised to $30 from $25 at H.C. Wainwright - Investing.com India

Sep 19, 2025
pulisher
Sep 19, 2025

NTLA: JMP Securities Reiterates Market Perform Rating | NTLA Stock News - GuruFocus

Sep 19, 2025
pulisher
Sep 19, 2025

Intellia Therapeutics Stock Gets A Price Target Hike From HC Wainwright – Check Out The Details - MSN

Sep 19, 2025
pulisher
Sep 19, 2025

Strength Seen in Intellia Therapeutics (NTLA): Can Its 29.8% Jump Turn into More Strength? - Yahoo Finance

Sep 19, 2025
pulisher
Sep 19, 2025

NTLA: HC Wainwright & Co. Raises Price Target to $30 | NTLA Stoc - GuruFocus

Sep 19, 2025
pulisher
Sep 19, 2025

H.C. Wainwright Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Raises Target Price to $30 - 富途牛牛

Sep 19, 2025
pulisher
Sep 19, 2025

Citizens JMP reiterates Market Perform rating on Intellia Therapeutics stock By Investing.com - Investing.com UK

Sep 19, 2025
pulisher
Sep 19, 2025

Intellia Therapeutics Advances Lonvo-z Toward 2026 LaunchKeep This One On Your Watchlist - RTTNews

Sep 19, 2025
pulisher
Sep 18, 2025

JonesTrading Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $25 - 富途牛牛

Sep 18, 2025
pulisher
Sep 18, 2025

Short Covering: What dividend growth rate does Intellia Therapeutics Inc offer2025 Market Sentiment & Growth Oriented Trade Recommendations - خودرو بانک

Sep 18, 2025
pulisher
Sep 18, 2025

Aug EndMonth: Why is Intellia Therapeutics Inc stock going upTrade Volume Summary & Long-Term Safe Investment Ideas - khodrobank.com

Sep 18, 2025
pulisher
Sep 18, 2025

Intellia stock rises after completing enrollment in Phase 3 HAE study By Investing.com - Investing.com South Africa

Sep 18, 2025
pulisher
Sep 18, 2025

Russell 2000 Hits All-Time Highs: 8 Stocks Power Small-Cap Comeback - Benzinga

Sep 18, 2025
pulisher
Sep 18, 2025

Intellia Therapeutics Shares Are Ripping Higher: Here's Why - Benzinga

Sep 18, 2025
pulisher
Sep 18, 2025

Earnings Update: Is Intellia Therapeutics Inc stock a hidden gemWeekly Trading Summary & Growth Focused Entry Reports - خودرو بانک

Sep 18, 2025
pulisher
Sep 18, 2025

Intellia Therapeutics (NTLA) Surges 20% on Trial Enrollment Comp - GuruFocus

Sep 18, 2025
pulisher
Sep 18, 2025

Intellia completes enrollment in phase 3 HAE gene therapy trial - Investing.com India

Sep 18, 2025
pulisher
Sep 18, 2025

Aug Catalysts: Can Intellia Therapeutics Inc sustain its profitabilityJuly 2025 Summary & High Return Trade Guides - khodrobank.com

Sep 18, 2025
pulisher
Sep 18, 2025

Retail Trends: Will Intellia Therapeutics Inc face regulatory challengesGlobal Markets & Trade Opportunity Analysis - خودرو بانک

Sep 18, 2025
pulisher
Sep 18, 2025

Intellia stock rises after completing enrollment in Phase 3 HAE study - Investing.com

Sep 18, 2025
pulisher
Sep 18, 2025

ARK Investment buys 560K shares of Intellia Therapeutics - MSN

Sep 18, 2025
pulisher
Sep 18, 2025

Intellia completes enrollment in phase 3 HAE gene therapy trial By Investing.com - Investing.com Nigeria

Sep 18, 2025
pulisher
Sep 18, 2025

Intellia Therapeutics Completes Enrollment in Phase 3 Study of Potential Hereditary Angioedema Treatment - MarketScreener

Sep 18, 2025
pulisher
Sep 18, 2025

Intellia rises after enrolling patients in late-stage trial of genetic disorder drug - TradingView

Sep 18, 2025

Intellia Therapeutics Inc (NTLA) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$35.77
price down icon 1.30%
$84.16
price down icon 0.45%
$29.45
price up icon 2.51%
$99.75
price up icon 1.51%
$141.00
price down icon 3.01%
biotechnology ONC
$329.84
price up icon 0.23%
大文字化:     |  ボリューム (24 時間):